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Abstract
Background: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies
that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients
who fail to respond to corticosteroids and immunosuppressive therapies. Recent basic science advances have led
to development of alternative treatments that specifically target aberrant pathways of fibrosis which are relevant to
disease progression in FSGS. There is a need for a flexible Phase II study design which will test such novel
antifibrotic strategies in order to identify agents suitable for phase III testing.
Methods/Design: The Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) project is a
multicenter Phase I/II RCT designed to investigate the potential efficacy of novel therapies for resistant FSGS.
Adalimumab and galactose will be evaluated against conservative therapy consisting of the combination of
lisinopril, losartan and atorvastatin. The sample size is defined to assure that if one of the treatments has a superior
response rate compared to that of the other treatments, it will be selected with high probability for further
evaluation. Comparison of primary and secondary endpoints in each study arm will enable a choice to be made of
which treatments are worthy of further study in future Phase III RCT.
Discussion: This report highlights the key features of the FONT II RCT including the two-step outcome analysis
that will expedite achievement of the study objectives. The proposed phase II study design will help to identify
promising agents for further testing while excluding ineffective agents. This staged approach can help to prevent
large expenditures on unworthy therapeutic agents in the management of serious but rare kidney diseases
Trial Registration: ClinicalTrials.gov, NCT00814255
Background
The goal of therapy in proteinuric diseases such as pri-
mary FSGS is complete remission of proteinuria and
preservation of renal function. However, this is rarely
achieved in patients with FSGS that is resistant to stan-
dard treatment [1,2]. When corticosteroids and immu-
nosuppressive therapy fail to induce remission in
patients with primary FSGS, a number of agents are
used as renoprotective therapy to delay progression of
chronic kidney disease (CKD) to end stage kidney
disease (ESKD). Angiotensin converting enzyme inhibi-
tor (ACEi) and angiotensin II receptor blocker (ARB)
are two such therapies that reduce proteinuria when
used alone, with an additive effect when prescribed in
combination [3-12]. Prescription of 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors
in doses designed to treat dyslipidemia is also associated
with stabilization of glomerular filtration rate (GFR) and
improved kidney function in chronic non-diabetic
nephropathies [13]. Combined use of an ACEi, an ARB,
and an HMG-CoA reductase inhibitors represents opti-
mal conservative medical therapy in patients with resis-
tant FSGS and has been advocated as a standard
renoprotective regimen [14-17].
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fibrosis. Tumor necrosis factor-a (TNF-a)i sa ni n f l a m -
matory cytokine produced by a wide range of cells
including macrophages and renal tubular epithelial cells.
Several mechanisms for TNF-a-induced proteinuria in
FSGS have been proposed including recruitment of leu-
kocytes to the site of glomerular injury, induction of
cytokines and growth factors, generation of oxygen radi-
cals with increased glomerular endothelial cell permeabil-
ity, cytotoxicity, and induction of apoptosis [18-21]. The
potential for TNF-a antagonism to reduce proteinuria in
resistant FSGS is based on the finding of elevated TNF-a
levels in experimental models of the disease and in
patients with FSGS, induction of proteinuria in animals
by TNF-a from mononuclear cells taken from patients
with FSGS, and reduction in proteinuria with a TNF-a
antagonist in the angiotensin II-induced renal injury
model and other models that resemble FSGS [22].
Published reports indicate that serum samples of
nearly 50% of patients with primary steroid resistant
FSGS have the capacity to increase the permeability of
glomeruli to albumin, (Palb)d u r i n gin vitro incubation
and testing [23]. Standard conditions for these studies
include incubation of glomeruli from normal rats with
medium containing 2% vol/vol patient serum. A value of
to ≥ 0.5 is defined as a positive test [24]. Addition of 10
-
12 M galactose to the incubation medium containing
patient serum completely prevents the increase in per-
meability. Removal of galactose by extensive dialysis of
the medium restores Palb activity. Intravenous adminis-
tration of galactose or chronic ingestion of galactose
prior to obtaining serum markedly decreases Palb activ-
ity. Dialysis of sera obtained after galactose administra-
tion does not restore activity, suggesting that galactose
enhances removal of a circulating permeability factor
[25]. Savin and colleagues have postulated that increased
hepatic clearance by galactose-binding proteins (galec-
tins) may be responsible for removal of the permeability
factor. There are case reports describing individual
patients with FSGS who were given oral galactose for
over 6 months and who demonstrated reduction in Palb,
lowering of proteinuria, and stabilization of kidney func-
tion [26]. These findings raise the possibility that
extended administration of galactose to lower Palb in
patients with resistant FSGS may reduce proteinuria and
delay progressive decline in kidney function [27].
The FONT trial (DK70341) is a combined Phase I/II
project with an overall objective to identify promising
new antifibrotic agents for further testing and distin-
guishing them from agents which are likely to be inef-
fective. A staged approach to drug evaluation is
incorporated into the Phase II trial design to avoid large
expenditures on unworthy and untested therapeutic
agents for this serious disease.
Methods/Design
Study Design: General considerations
FONT II is a Phase II open-label RCT to choose which
treatment or treatments are worthy of further study in
future Phase III studies.
Specific Aims
1. To evaluate two novel therapies for resistant FSGS -
adalimumab, a human anti-TNF-a antibody, and galac-
tose - compared to standard conservative therapy;
2. To identify one or more novel agents as candidates
for evaluation in a future Phase III RCT; and
3. To create and sustain an infrastructure for the
timely completion of RCTs in patients with rare glomer-
ular diseases like primary FSGS.
Primary and Secondary Outcomes
There will be a composite endpoint in which a patient
will be classified as having a positive response if both of
the following criteria are satisfied:
￿ Reduction in proteinuria (expressed as the protein:
creatinine ratio in a first morning urine specimen) at
6m o n t h sb y≥ 50% of the value at the time of
screening, AND
￿ Estimated GFR (eGFR) at 6 months ≥ 75% of the
value at the time of randomization in those with an
initial eGFR <75 mL/min/1.73 m
2 OR eGFR persis-
tently ≥75 mL/min/1.73 m
2 in those whose renal
function was ≥75 mL/min/1.73 m
2 a tt h et i m eo f
randomization.
The proteinuria at the time of screening will be used to
determine eligibility and efficacy. While an eGFR ≥40 mL/
min/1.73 m
2 at screening will be used to determine elig-
ibility, the eGFR at the time of randomization will be used
to determine efficacy to account for the hemodynamic
impact of intensified combination therapy with ACEi and
ARB agents during the Run-In Phase (see below).
The proteinuria endpoint is an objective variable that
can be quantitated in a bias-free manner. Although con-
troversy remains over the potential use of proteinuria as
a surrogate end point in definitive Phase III clinical
trials, proteinuria is an ideal marker for use as an inter-
mediate outcome in earlier phase trials. In particular,
proteinuria responds to many therapies within several
months, providing an outcome whose response can be
assessed in relatively short-term studies [28]. The protei-
nuria component of the composite was formulated to
r e q u i r eal a r g ec h a n g e( ≥50% reduction) to increase the
likelihood that changes classified as a positive outcome
a r ec l i n i c a l l yr e l e v a n ta n dt or e d u c et h ei n f l u e n c eo f
small perturbations as might be induced by minor
hemodynamic changes. However, due to concerns that
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declining kidney function rather than improvement in
glomerular permselectivity, stabilization of eGFR is
included in a composite primary endpoint. eGFR will be
calculated using the Schwartz equation in patients ≤18
years of age at screening or the Cockroft Gault equation
adjusted for body surface area in patients older than 18
years of age, in accord with procedures adopted in the
FONT Phase I studies [29-31].
The composite primary outcome will be assessed in all
patients enrolled in the trial and who are randomized to
one of the three study treatments. In a subgroup analy-
sis, the primary endpoint will be evaluated in the
patients in the three experimental groups whose Palb at
the time of enrollment exceeds 0.5.
Secondary Endpoints
Key secondary renal endpoints will include the percent
change in the first morning urine protein creatinine ratio
from baseline to 6 months, the change in eGFR from base-
line to 6 months, both evaluated as continuous variables,
and time to a 50% reduction in eGFR and/or ESKD.
Patient status [32], and quality of life will be assessed by
age-appropriate QOL surveys and the Patient-Reported
Outcomes Measurement Information System (PROMIS)
score. The adverse effect profile will be determined by
clinical evaluation and standard laboratory testing.
Study Population
Inclusion and exclusion criteria for enrollment are
defined in Table 1. The eligibility criterion for steroid
resistance or intolerance is defined in recognition of a
reluctance of nephrologists to routinely administer a pre-
scribed course of corticosteroids to all patients because
of the potential for serious adverse events. FSGS can
occur as a consequence of genetic mutations in structural
proteins in the podocyte [33-36]. Thus, confirmation of a
disease-causing mutation in a podocyte protein is an elig-
ibility criterion for the FONT II trial in patients who lack
biopsy-confirmation of the diagnosis of FSGS. Although
there is a lack of data on expected response rates to anti-
fibrotic therapy in the presence or absence of podocyte
mutations, progressive renal fibrosis is an intrinsic fea-
ture of primary FSGS, regardless of whether or not there
is a defined genetic mutation. In any event, DNA speci-
mens for storage in the NIDDK Biorepository will be
obtained from all patients who enroll in the trial and con-
sent to the procedure. There is no exclusion criterion
based on obesity because antifibrotic agents should also
be beneficial in patients with obesity-related FSGS.
Screening and Run In Phase
In order to achieve a comparable baseline assessment of
proteinuria and GFR prior to initiation of one of the
novel therapies, the patients will be taken off all immu-
nosuppressive medications including corticosteroids
(except for a minimal daily or alternate-day dosage to
control edema if clinically indicated) for 30 days. In
addition, patients will be placed on the maximal toler-
ated doses of lisinopril, losartan or atorvastatin, based
on measurements of blood pressure, serum potassium,
creatinine, and cholesterol concentrations. Patients must
be on stable doses of the ACEi/ARB treatment for a
minimum of 2 weeks prior to randomization into the
FONT Phase II study to insure that the initiation of
novel therapy does not coincide with a hemodynamically
induced change in proteinuria. In order to fully imple-
ment the conservative medical therapy regimen in a
timely manner, a maximum 12 week Screening/Run-In
period will precede randomization (Figure 1).
Study Medications
Standard conservative medical therapy: All patients will
r e c e i v eac o m b i n a t i o no ft h ef o l l o w i n gt h r e ea g e n t s :1 )
lisinopril: 2) losartan; and 3) atorvastatin. The maximum
doses for patients weighing <40 kg will be: lisinopril 10
mg, losartan 25 mg, and atorvastatin 10 mg. For patients
weighing >40 kg, the maximal doses will be: lisinopril 20
mg, losartan 50 mg, and atorvastatin 20 mg. Stable
dosages of the ACEi and ARB must be achieved by the
end of the Screening/Run-in period (2-12 weeks) and
remain unchanged for the duration of the 6 month
treatment period barring any clinical or laboratory side
effects.
The following novel therapies will be administered for
6 months before assessing efficacy;
Adalimumab (Humira
®): TNF-a antibody: The thera-
peutic dose of adalimumab will be 24 mg/m
2 (maximum
dose: 40 mg) every other week as a subcutaneous injec-
tion for the entire treatment period. Although the phar-
macokinetics (PK) data from the FONT Phase I Study
indicated enhanced clearance of adalimumab in patients
with FSGS and nephrotic-range proteinuria, the dose
will not be increased above the standard amount in
order to minimize the risk of adverse events [30,31].
Galactose: sugar: Galactose (Ferro Pfanstiehl, Wauke-
gan, IL), 0.2 g/kg per dose (maximum dose: 15 g) will
be administered orally twi c ead a y .T h es u g a rw i l lb e
dissolved in 15-30 ml of water and the liquid will be
ingested 15-30 minutes before breakfast and dinner.
Study Protocol
F i g u r e1o u t l i n e st h ec o u r s eo ft h eP h a s eI It r i a la f t e r
completion of the Screening/Baseline period and receipt
of study drugs at week 0. Patients will be evaluated after
2, 8, 16, and 26 weeks of the assigned experimental
treatment. A follow-up evaluation will be performed at
1 month, 3 months, and 6 months after discontinuation
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end of the funding period.
Study Mandated Stop Points
￿ > 50% decline from baseline eGFR and <60 mL/
min/1.73 m
2 OR a final level <20 mL/min/1.73 m
2
￿ ESKD, i.e., initiation of dialysis or receipt of a renal
transplant
￿ Serious Adverse Event (SAE), i.e. grade 4 Common
Toxicity Criteria (CTC) toxicity
￿ Increase in ALT/AST to >2.5× the upper limit of
normal
￿ Onset of congestive heart failure or a myocardial
infarction
￿ Clinical onset of SLE and/or positive ANA ≥1:160
￿ Serious infection/sepsis
￿ Malignancy
￿ Pregnancy
Statistical Considerations, Efficacy and Power
A hybrid Phase II design as described by Liu et al [37]
will be used which incorporates a ranking/selection
comparison [38,39] between the treatment groups as
well as a minimum activity requirement within each
treatment group. FONT II will include a sample size of
42 patients in each of the three treatment arms, with a
total sample size of 126 patients. Up to 53 patients may
be enrolled in the galactose arm (137 total subjects) to
ensure a subgroup of 42 with a Palb >0 . 5 .A l t h o u g ht h e
Table 1 FONT II Study Eligibility Criteria
Inclusion Criteria
1. Primary FSGS confirmed by renal biopsy
2. Failure to respond to prior therapy with at least one of the following immunosuppressive medications – cyclosporine, tacrolimus, mycophenolate
mofetil, sirolimus - or other agents prescribed to lower proteinuria
3. Age 1-50 years at onset of proteinuria
4. Age 1-51 years at time of randomization
5. Estimated GFR ≥40 mL/min/1.73 m
2 using Schwartz (age <18 yr) or Cockcroft-Gault (age ≥ 18 yr) formula at screening and ≥30 mL/min/1.73 m
2
at the end of the Run-In Period and prior to randomization
6. Up/c > 1.0 g protein/g creatinine on first morning void
7. Steroid resistance defined as failure to achieve sustained Up/c < 1.0 following a standard course of prednisone/prednisolone/methylprednisolone
prescribed for FSGS therapy, OR contraindication/anticipated intolerance to steroid therapy defined as severe obesity, documented decreased bone
density, family history of diabetes, or a psychiatric disorder.
8. Willingness to follow the protocol, including medications, baseline and follow-up visits, and procedures.
Exclusion Criteria
1. Lactation, pregnancy, or refusal of birth control in women of child-bearing potential
2. Participation in another therapeutic trial involving protocol mandated administration of a immunosuppressive medication concurrently or 30 days
prior to randomization
3. Active/serious infection (including, but not limited to Hepatitis B or C, HIV)
4. History of malignancy
5. Abnormality in age appropriate cancer screening in accord with ACS 2003 guidelines
6. Patients with uncontrolled blood pressure > 140/90 or > 95th percentile for age/height at the end of the run in period
7. Diabetes mellitus, type 1 or 2
8. Organ or bone marrow transplantation
9. Congestive heart failure
10. History of myocardial infarction
11. SLE or multiple sclerosis
12. Hepatic disease defined as serum ALT/AST more than 2.5× the upper limit of normal
13. Hematocrit <27 vol%
14. Immunosuppressive therapy with cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, rapamycin, or cyclophosphamide in the 30 days
prior or Rituximab in the 90 days prior to randomization
15. Use of corticosteroids in the last 30 days except for minimal dosage required for stabilization of edema
16. Prior treatment with the study medications, galactose or adalimumab
17. Allergy to one of the study medications, i.e., adalimumab, galactose, lisinopril, losartan, atorvastatin
18. Abnormal Pap smear (more than carcinoma in situ 1) unless treated and follow-up indicates a normal Pap smear
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patient enrollment was very low prior to this change.
Therefore, introduction of galactose and removal of
rosiglitazone are not anticipated to influence the study
population. We next describe the assessment of the
minimum activity requirement and the ranking/selection
components of the study.
Minimum efficacy component: A two-stage procedure
will be conducted to determine if the individual novel
experimental treatments achieve a minimal level of effi-
cacy that would signify that the therapies are sufficiently
promising to warrant further investigation. In the first
stage, patients will be enrolled until each of the 3 treat-
ment groups has accumulated 17 randomized subjects.
At this point, randomization will be temporarily halted,
and there will be a 6 month pause during which the
first set of patients assigned to each of the 3 arms will
be allowed to complete the treatment period and have
their response to the therapy evaluated. If in either of
the experimental groups - adalimumab or galactose
groups– there are one or fewer responders among the
first 17 randomized patients, that group will be dropped
from further consideration. After the 6-month pause,
the study will resume randomization until 42 patients
(up to 53 patients may be enrolled in the galactose arm
t oe n s u r eas u b g r o u po f4 2w i t haP alb >0 . 5 )a r e
accrued for each agent that passed the initial efficacy
threshold.
This component of the design is based on the para-
meters p0, the estimated response rate to an “ineffective
novel therapy”, and p1, the projected response rate to
an “effective novel therapy” that we would like to evalu-
a t ei naR C T .B a s e do ne x p e r i e n c eg a t h e r e df r o mt h e
Glomerular Disease Collaborative Network (University
of North Carolina, Chapel Hill, NC), we anticipate that
optimal conservative medical therapy will result in
response rate (≥50% reduction in proteinuria) of
approximately 10%. Taking p0 = 10% and p1 = 30%
(designating a 20% improved response for a successful
novel therapy), the two-stage procedure described above
has Type I and Type II error rates of 2% and 10%,
respectively. Any treatment with at least 9 responses
(out of 42 patients) will be identified as having a
response rate sufficiently greater than 10% and
Timeline (weeks) 
-12 weeks                                                SCREENING
-12-0 weeks                                                RUN-IN 
  0 week                                        BASELINE ASSESSMENT 
  0 week                                           RANDOMIZATION TO  
                                                        STUDY INTERVENTION 
                                  ADALIMUMAB          GALACTOSE                       CONSERVATIVE 
  26 weeks                                          PRIMARY OUTCOME 
                                                                 ASSESSMENT                                            
                                                         POST INTERVENTION  
                                                                MONITORING 
Figure 1 FONT II Trial Design.
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study in subsequent Phase III RCT.
T h er e q u i r e m e n to f2o rm o r er e s p o n s e sf o rt h et w o
experimental treatments in the first stage reduces the
risk of continuing to enroll patients into a treatment
group for which the early results indicate a low response
rate. On the other hand, the 2-stage design has at least a
98% probability of proceeding to the second stage if the
true response rate of either of the two initial experimen-
tal treatments is 30% or greater. The overall type I and
II error rates of 2 and 10% indicate that for each treat-
ment group, the proposed design has a probability of 2%
of incorrectly designating a regimen with a 10%
response rate as “active”, and a probability of 90% of
correctly designating a regimen with a 30% response
rate as “active”.
Ranking Selection Component
The ranking/selection component of the design com-
pares the response rates between the treatment groups,
and selects the treatment regimen with the best
response rate, irrespective of how large or small the
a d v a n t a g eo v e rt h eo t h e r sm a yb e .T h es a m p l es i z ei n
such a selection design is selected to assure that if one
of the treatments has an underlying response rate which
is clearly superior to that of the other treatments; it will
be selected with high probability. FONT II includes a
sample size of 42 (up to 53 patients may be enrolled in
the galactose arm to ensure a subgroup of 42 with a Palb
> 0.5) patients in each of the 3 treatment groups for a
total sample size of 126. This will insure that the treat-
ment with the best response rate will be correctly
selected with a probability of 85% if one of the treat-
ments has a response rate ≥40% and all the remaining
treatments have response rates no higher than 25%.
Subgroup Analysis
It is anticipated that approximately 80% of the enrolled
patients will have Palb > 0.5. This value represents the
lower limit for increased levels of the permeability fac-
tor, which is the putative target of galactose treatment.
Therefore, a secondary analysis will be performed in
which the response rate of the Galactose arm will be
computed separately for the subgroup with Palb >0 . 5 .
The ranking-selection comparison of all three groups
will also be repeated in patients with Palb > 0.5.
Ethics of Human Subject Research
The use of the full array of experimental therapies in the
FONT Phase II Trial has been authorized by the FDA
(IND # 100,037). The study protocol, design and con-
sent forms have been approved by Institutional Review
Board (IRB) at the two clinical coordinating centers -
Cohen Children’s Medical Center of New York and
University of Michigan-CS Mott Children’sH o s p i t a l-
and 13 other participating sites (Nationwide Children’s
Hospital, Boston Children’s Hospital, Oregon Health
Sciences Center, Miami Children’s Hospital, Carolinas
Medical Center, Stollery Children’s Hospital, Medical
University of South Carolina, Emory University, Texas
Tech University Health Sciences Center, Children’s
Mercy Hospital, University of Kansas, Mayo Clinic, and
Cincinnati Children’s Medical Center). Specific study
elated information will be made available to the Food
and Drug Administration (FDA) and the National Insti-
tutes of Health (NIH). All procedures will be in compli-
ance with Health Information Portability and
Accountability Act (HIPAA) regulations. The trial is
funded primarily by the National Institutes of Health-
NIDDK (DK70341) with a small supplemental grant
from the NephCure Foundation. The project is listed at
ClinicalTrials.gov with the identifier NCT00814255.
Discussion
FSGS is a clinical entity with a distinctive histopatholo-
gical appearance, which is either primary or secondary
to other etiologies. This lesion accounts for 10-20% of
cases of primary nephrotic syndrome in children and up
to 35% of cases in adults. In the majority of patients, the
primary lesion is refractory to therapeutic interventions
with immunosuppressive agents. The final common
pathway for advancing disease in primary FSGS is pro-
gressive fibrosis leading to ESKD, which occurs in 50 to
75% of patients over a 10-year period [1,2,40-42]. The
morbidity and mortality of patients with FSGS is com-
pounded by that of superimposed ESRD. The life expec-
tancy for a 10-year old child who is dialysis-dependent
is reduced by approximately 30 to 50 years from the
current 84 years in the general US population. Following
renal transplantation for FSGS, a high recurrence rate
results in a 20-25% allograft loss and further diminishes
the likelihood of long-term graft and patient survival.
Thus, the longevity of patient survival is directly linked
to success in treating FSGS and prolonging native kid-
ney survival [43-45].
The lack of adequate RCTs has hindered clinical
research in the treatment of FSGS. The majority of stu-
dies that have evaluated potential therapies for FSGS
have either been uncontrolled, had poorly defined end-
points, or had treatment periods of insufficient length
[1,46]. This has engendered a great deal of controversy
about the optimal treatment of FSGS and variability in
p r a c t i c ef r o mt h eo n s e to fd i s e a s ea n dt h r o u g h o u ti t s
course. Cyclosporine is the only drug that has been eval-
uated and demonstrated by RCT to be useful in pedia-
tric and adult patients [1,2]. The lack of effective agents
if cyclosporine fails is underscored by the observation
that only 1 out of 14 invited articles dealing with FSGS
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been studied in small uncontrolled patient cohorts [47].
This report describes an RCT whose objective is to
evaluate potential efficacy of novel therapies that target
reduction in renal fibrosis as their main mechanism of
action. While this may be an off-target mechanism rela-
tive to the approved indication for the test agents,
reduction in fibrosis is primary effect in the context of
FSGS. However, a major challenge for this type of trial
is the development of a dynamic study design aimed at
efficiently identifying novel therapeutic approaches and
on avoiding large expenditures on unworthy and
untested therapeutic agents for serious diseases. The
novelty of this project centers on the application of a
distinct two step analysis of outcomes to expedite the
identification of agents suitable for Phase III testing in
patients with a rare glomerular disease, namely treat-
ment-resistant FSGS.
Rosiglitazone was evaluated in the FONT I project
[29] and was originally included as a treatment arm in
the FONT II trial based on ample preclinical evidence
that this drug has antifibrotic properties. However,
recent meta-analyses of clinical trials in adults with type
2 diabetes suggest that treatment with thiazolidinediones
is associated with an increased risk of myocardial infarc-
tion and possibly with overall cardiovascular morbidity
and mortality [48,49]. It is unclear if this adverse effect
is unique to rosiglitazone or is a class effect that also
impacts on the use of the related agent pioglitazone.
Although patients with primary FSGS differ from those
with type 2 diabetes making it difficult to generalize the
risk of serious adverse events from the latter to the for-
mer group, concerns about the feasibility of timely
recruitment into the FONT Phase II trial forced aban-
donment of the rosiglitazone arm, leaving a 3-arm study
that compares conservative medical therapy, adalimu-
mab, and galactose. The study incorporates comprehen-
sive surveillance for cancer detection because of the
increase risk of malignancy in patients treated with
TNF-a antagonists [50].
Because of the low incidence and prevalence of
patients with FSGS, an efficient and productive study
design that fosters collaboration is essential to imple-
ment cost-effective trials and to identify and recruit clin-
ical subjects in a timely manner. While conducting
Phase I studies, the FONT consortium developed a
functional infrastructure that will sustain collaboration.
This should hasten the successful performance of stu-
dies seeking to develop new therapeutic interventions
that will improve the care and outcome of patients with
FSGS. The support of the NephCure Foundation, which
is dedicated to advancing research into the pathogenesis
and treatment of FSGS, has facilitated the creation of
the cooperative network and fostered awareness and
enthusiasm for the study among patients and their
families.
It is anticipated that the proposed clinical trial metho-
dology will overcome existing difficulties involved in the
s t u d yo fr a r ek i d n e yd i s e a s e sb yi m p l e m e n t i n gc o s t -
effective approaches aimed at identifying novel thera-
peutic approaches and by avoiding large expenditures in
the evaluation of unworthy and/or unsafe therapeutic
agents for serious glomerular disorders like FSGS.
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